Future studies on SGLT2 inhibitors are expected to continue to focus on heart failure and diabetic cardiomyopathy, as well as delve further into the relevant molecular mechanisms, especially those related to fibrosis and AMPK. Here, SLC5A2 is linked to heart failure.